FDA Approves January 26, 2025, Monthly Maintenance Dosing for Eisai/Biogen's lecanemab-irmb in Early Alzheimer's Treatment

Jan 27, 2025, 02:46 AM

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing of LEQEMBI® (lecanemab-irmb) for the treatment of early Alzheimer's disease. This decision, announced on January 26, 2025, allows for intravenous administration of the drug developed by Eisai Co. Ltd. and Biogen. The approval signals a significant advancement in the treatment options available for early-stage Alzheimer's patients, providing a new avenue for ongoing management of the disease.